Dossier - 22/02/2010 Respiratory disease - congestion in the respiratory system Lung diseases are by far the most frequent cause of death worldwide. Every year three million people die from chronic obstructive pulmonary diseases 2.3 million die from lung cancer and 1.5 die from tuberculosis WHO World Health Organisation. There is no improvement in sight and experts believe that the number of deaths will continue to rise particularly in the case of chronic obstructive pulmonary diseases COPD lung cancer and tuberculosis TB.…https://www.gesundheitsindustrie-bw.de/en/article/dossier/respiratory-disease-congestion-in-the-respiratory-system
Press release - 19/01/2010 Affimed Therapeutics AG Completes Move Into Drug Development Affimed Therapeutics AG, the therapeutic antibody company from Heidelberg, announced today that it is now concentrating all activities on the exclusive development of its in-house drug candidates derived from the company's proprietary TandAb technology platform. In line with this, the Company has spun-out its antibody discovery activities into a new company: AbCheck s.r.o, (Plzen, Czech Republic). https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-therapeutics-ag-completes-move-into-drug-development
Article - 20/10/2008 Dangerous hide and seek game in the lungs A group of researchers led by Prof. Dr. Frank-Michael Müller from Heidelberg has shown that mould fungi like Aspergillus fumigatus are able to develop biofilms in the lungs and protect themselves against the bodys immune defence system and drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dangerous-hide-and-seek-game-in-the-lungs
Article - 30/06/2008 Boehringer Ingelheim to acquire US biotech company Boehringer Ingelheim has announced an agreement to acquire Actimis Pharmaceuticals based in San Diego for 515 million US dollars. Boehringer is specifically targeting an asthma compound developed by Actimis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-to-acquire-us-biotech-company
Article - 17/02/2008 Nycomed extends geographic reach Nycomed is about to establish its own marketing and sales organisation in Venezuela. With this the company will operate from an own subsidiary in all four leading Latin American pharmaceutical markets Mexico Brazil Venezuela and Argentina.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-extends-geographic-reach
Press release - 15/01/2008 ALVESCO® gains FDA approval for the U.S. market The Food and Drug Administration approved Nycomeds ALVESCO ciclesonide Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older.https://www.gesundheitsindustrie-bw.de/en/article/press-release/alvesco-gains-fda-approval-for-the-u-s-market